Related references
Note: Only part of the references are listed.Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Ralf Gold et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Cladribine: Mode of Action and Implications for Treatment of Multiple Sclerosis
Thomas P. Leist et al.
CLINICAL NEUROPHARMACOLOGY (2011)
Multiple sclerosis as a neurodegenerative disease: pathology, mechanisms and therapeutic implications
Christine Stadelmann
CURRENT OPINION IN NEUROLOGY (2011)
Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients
A. Kerbrat et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2011)
Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis
Gavin Giovannoni et al.
LANCET NEUROLOGY (2011)
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study
S. Cook et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
T2 lesions and rate of progression of disability in multiple sclerosis
J. P. Mostert et al.
EUROPEAN JOURNAL OF NEUROLOGY (2010)
Current and future disease-modifying therapies in multiple sclerosis
S. Y. Lim et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Effects of disease modifying treatments on cognitive dysfunction in multiple sclerosis
Giancarlo Comi
NEUROLOGICAL SCIENCES (2010)
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
Gavin Giovannoni et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Jeffrey A. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Magnetic Resonance Imaging Predictors of Conversion to Multiple Sclerosis in the BENEFIT Study
Bastiaan Moraal et al.
ARCHIVES OF NEUROLOGY (2009)
MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome
Jessica M. Nielsen et al.
BMC NEUROLOGY (2009)
One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis
L. Prosperini et al.
EUROPEAN JOURNAL OF NEUROLOGY (2009)
New options for early treatment of multiple sclerosis
Mar Tintore
JOURNAL OF THE NEUROLOGICAL SCIENCES (2009)
Post-marketing of disease modifying drugs in multiple sclerosis: An exploratory analysis of gender effect in interferon beta treatment
M. Trojano et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2009)
GLANCE Results of a phase 2, randomized, double-blind, placebo-controlled study
A. D. Goodman et al.
NEUROLOGY (2009)
Disability and T2 MRI lesions:: a 20-year follow-up of patients with relapse onset of multiple sclerosis
L. K. Fisniku et al.
BRAIN (2008)
Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
G. Comi et al.
LANCET (2008)
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
Daniel D. Mikol et al.
LANCET NEUROLOGY (2008)
The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation
Thomas P. Leist et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Magnetic resonance Imaging effects of interferon beta-1b in the BENEFIT study - Integrated 2-year results
Frederik Barkhof et al.
ARCHIVES OF NEUROLOGY (2007)
The place of MRI in monitoring the individual MS patient
Douglas L. Arnold
JOURNAL OF THE NEUROLOGICAL SCIENCES (2007)
Predicting short-term disability in multiple sclerosis
S. A. Gauthier et al.
NEUROLOGY (2007)
Glatiramer acetate in multiple sclerosis: A review
Maddalena Ruggieri et al.
CNS DRUG REVIEWS (2007)
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS
D. H. Miller et al.
NEUROLOGY (2007)
New natural history of interferon-β treated relapsing multiple sclerosis
Maria Trojano et al.
ANNALS OF NEUROLOGY (2007)
Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study
Richard A. Rudick et al.
ANNALS OF NEUROLOGY (2006)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A longitudinal study of abnormalities on MRI and disability from multiple sclerosis
PA Brex et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Final analysis of the European multicenter trial on IFNβ-1b in secondary-progressive MS
L Kappos et al.
NEUROLOGY (2001)
Short-term prognosis in early relapsing-remitting multiple sclerosis
TF Scott et al.
NEUROLOGY (2000)
Share Paper
